Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1250 participants
OBSERVATIONAL
2022-06-21
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The secondary objective is the development and the test of diagnostic accuracy of an AI algorithm to predict tumor aggressiveness from mpMRI images.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Creation of an Image Database for the Development of a Computer Aided Diagnostic (CAD) System in Patients With Prostate Cancer
NCT02618200
Assessment of Prostate MRI Before Prostate Biopsies
NCT02485379
Evaluation of Rapid T2-weighted and DWI MR Sequences Reconstructed by Deep Learning for Prostate Imaging
NCT06094322
Deep Learning for Prostate Segmentation
NCT04191980
Targeted And Perilesional Or Systematic Biopsy In Prostate Cancer
NCT07296042
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Firstly a sub-study with a multicentric retrospective sample of 700 patients from the databases of AP-HP, CHU de Lyon and CHU de Lille for training and validation of algorithms. The historical depth may be up to 96 months (8 years)
2. A second sub-study with a multicentric prospective sample of 550 patients (test-set) associating AP-HP (CHU Pitié, Tenon, Bicêtre, Necker), CHU Lille, CHU Lyon, CHU Bordeaux and CHU Strasbourg to test the performance of algorithms Data will be collected retrospectively (training phase - validation of the algorithm) and prospectively (testing phase of the algorithm) from the medical records of each of the centres for patients corresponding to the inclusion and exclusion criteria mentioned above.
Methodology :
1. Retrospective phase mpMRI images chained to histological (prostate biopsy data), biological (PSA) and demographic (age) data will be used for supervised learning during the training and validation phases. Thus, the aggressiveness scores will rely on a matching between mpMRI images and the results of targeted biopsies in addition to standard biopsies
2. Prospective phase For the performance measurement, a test set of 550 prospectively collected images will be used, of which 150 will be from the same centers, and 400 from 3 other clinical centers (CHU Strasbourg, APHP Bicêtre and Necker-HEGP and CHU Bordeaux).
The algorithms developed in the retrospective phase will be applied by Inria to the prospective data, without knowledge of the PI-RADS score or the aggressiveness. The performance of each algorithm will then be evaluated, under the responsibility of an independent unit,by its sensitivity and specificity with their IC95%. The main analysis will be conducted by patient (presence of at least one lesion with a PI-RADS score ≥3; presence of at least one lesion considered aggressive (defined by the presence of a histological Gleason score grade 4 up to 6 months after the mpMRI). Secondary analyses will be conducted by lesion and by prostate lobe.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Retrospective group
Retrospective group: 700 patients from the databases of the AP-HP, the Lyon University Hospital and the Lille University Hospital for training and validation of the algorithms.
No interventions assigned to this group
Prospective group
Prospective group: 550 patients (test-set) from AP-HP (CHU Pitié, Tenon, Bicêtre, Necker), CHU Lille, CHU Lyon, CHU Bordeaux and CHU Strasbourg to tes the performance of the algorithms.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with clinical suspicion of prostate cancer (increased PSA level and/or abnormality on digital rectal examination) who should receive a diagnostic workup including mpMRI and prostate biopsies according to national recommendations: in case of normal mpMRI (PI-RADS \< 3) 12 systematic samples; in case of pathological mpMRI (PI-RADS ≥3) 12 systematic samples associated with targeted samples (n= 2 to 4) by cognitive fusion, or image fusion software.
Exclusion Criteria
Prospective substudy
* Patients with already histologically proven cancer, patients who have received treatment for prostate cancer, patients who cannot benefit from prostate biopsies, or patients with a contraindication to performing mpMRI.
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Strasbourg, France
OTHER
University Hospital, Bordeaux
OTHER
University Hospital, Lille
OTHER
The Civil Hospitals, Lyon
UNKNOWN
Institut National de Recherche en Informatique et en Automatique
OTHER
INCEPTO
UNKNOWN
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
La Pitié Salpétrière Hospital
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
APHP201101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.